Talha Badar, Hematology/Oncology specialist at Mayo Clinic, shared a post on X:
“Improved outcomes and treatment guidance in pediatric therapy-related AML: AML-BFM study group recommendations
10 years OS post allo-HCT in recent decade up to 50% +/- 10%. Adverse cytogenetics, previous ionizing radiation (>35 Gy), and latency ≤1 year were identified as the strongest poor prognosticators. “
Title: Improved outcomes and treatment guidance in pediatric therapy-related AML: AML-BFM study group recommendations
Authors: Stephanie Sendker, Markus Schneider, Evangelia Antoniou, Daniel Neumann, Naghmeh Niktoreh, Uta Dirksen, Nils von Neuhoff, Ursula Creutzig, Dirk Reinhardt, Katharina Waack
Also read “Key Insights by Talha Badar from ASCO25” on OncoDaily.
